Key Takeaways
- • Former Mural Oncology CEO secured $225 million in venture capital funding to launch a new cancer-focused biotech company specializing in engineered cytokines for oncology treatment.
- • Mural Oncology was previously spun out of Alkermes in November 2023 and subsequently acquired by Xoma in August 2025, establishing a track record of strategic M&A activity within the founder's portfolio.
- • The new venture positions the founder to advance a pipeline of engineered cytokines, a therapeutic approach gaining traction in immuno-oncology as alternatives to traditional cancer treatments.
- • This capital raise reflects continued investor appetite for oncology-focused biotech ventures led by experienced executives with demonstrated success in building and scaling cancer drug pipelines.
Summary
A former CEO of Mural Oncology has launched a new cancer biotech company backed by $225 million in venture capital funding. The newly founded venture will focus on developing and advancing a pipeline of engineered cytokines for cancer treatment, targeting the immunotherapy and oncology segments of the biotech market.
The founder's oncology track record includes leadership of Mural Oncology, which was spun out of neuroscience-focused Alkermes in November 2023. Mural was subsequently acquired by Xoma in August 2025, demonstrating successful exit execution and providing institutional validation of the founder's ability to build and commercialize oncology assets. This serial entrepreneurship in cancer therapeutics, combined with the substantial $225 million Series funding round, signals confidence from venture investors in the leadership team's ability to navigate drug development and commercialization in a competitive oncology market.
Engineered cytokines represent an evolving therapeutic modality within cancer immunotherapy. As a class, cytokines are signaling proteins that regulate immune responses, and engineered variants are designed to enhance efficacy while potentially reducing side effects compared to conventional approaches. This therapeutic focus aligns with the broader industry shift toward next-generation immunotherapy platforms beyond CAR-T and checkpoint inhibitors.
The timing of this capital raise occurs within a robust venture funding environment for oncology-stage biotechs, where investor interest remains high despite market volatility in public biotech equity markets. The founder's prior experience scaling Mural through acquisition, combined with institutional backing from seasoned venture investors, positions this new entity to recruit experienced management, advance clinical programs, and potentially pursue strategic partnerships or additional financing as pipeline assets progress through development.
The founder's oncology track record includes leadership of Mural Oncology, which was spun out of neuroscience-focused Alkermes in November 2023. Mural was subsequently acquired by Xoma in August 2025, demonstrating successful exit execution and providing institutional validation of the founder's ability to build and commercialize oncology assets. This serial entrepreneurship in cancer therapeutics, combined with the substantial $225 million Series funding round, signals confidence from venture investors in the leadership team's ability to navigate drug development and commercialization in a competitive oncology market.
Engineered cytokines represent an evolving therapeutic modality within cancer immunotherapy. As a class, cytokines are signaling proteins that regulate immune responses, and engineered variants are designed to enhance efficacy while potentially reducing side effects compared to conventional approaches. This therapeutic focus aligns with the broader industry shift toward next-generation immunotherapy platforms beyond CAR-T and checkpoint inhibitors.
The timing of this capital raise occurs within a robust venture funding environment for oncology-stage biotechs, where investor interest remains high despite market volatility in public biotech equity markets. The founder's prior experience scaling Mural through acquisition, combined with institutional backing from seasoned venture investors, positions this new entity to recruit experienced management, advance clinical programs, and potentially pursue strategic partnerships or additional financing as pipeline assets progress through development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.